Last $4.30 USD
Change Today -0.025 / -0.58%
Volume 1.5M
XOMA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 1:14 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2910 Seventh Street

Berkeley, CA 94710

United States

Phone: 510-204-7200

Fax:

XOMA Corporation discovers and develops innovative antibody-based therapeutics, including those that have allosteric modulating properties. The company’s primary product candidate, gevokizumab, is a proprietary potent, fully humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). Together with its development partner, Les Laboratoires Servier (Servier), an independent French pharmaceutical company, the company initiated three Phase 3 clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behçet’s uveitis, a severe subset of NIU. The company is responsible for all of the clinical study sites in the United States and Servier is responsible for all of the clinical study sites outside of the United States. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behçet’s uveitis), and EYEGUARD-C (patients controlled with systemic treatment). In addition to the NIU clinical trials, the company is conducting a trial of gevokizumab in pyoderma gangrenosum (PG), a rare ulcerative skin disease. Proprietary Products Gevokizumab is a proprietary potent humanized monoclonal antibody with allosteric modulating properties and has the potential to treat patients with various inflammatory diseases. Gevokizumab binds to IL-1 beta, a pro-inflammatory cytokine involved in NIU and Behçet’s uveitis, PG, active non-infectious anterior scleritis, cardiovascular disease, diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases. By binding to IL-1 beta, gevokizumab modulates the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation. The company has an agreement with Servier to jointly develop and commercialize gevokizumab in multiple indications. Under the terms of that agreement, Servier has worldwide rights to gevokizumab for cardiovascular disease and diabetes indications and rights outside the United States and Japan to all other indications. The company retains development and commercialization rights in the United States and Japan to all indications except cardiovascular disease and diabetes and has an option to reacquire rights to these indications from Servier in these territories. In 2013, Servier also began testing gevokizumab in various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. XMet (XOMA Metabolic Activating, Sensitizing and Antagonizing/Deactivating Antibodies): Selective insulin receptor modulators, such as allosteric modulating antibodies activate (XMet A), are designed to provide long-acting insulin-like activity to diabetic patients who cannot make sufficient insulin, reducing various insulin injections needed to control their blood glucose levels. Insulin receptor-sensitizing antibodies, such as allosteric modulating antibodies sensitize (XMet S), are designed to reduce insulin resistance and could enable diabetic patients to use their own insulin to control blood glucose levels. Insulin receptor deactivating/antagonizing antibodies, such as allosteric modulating antibodies deactivate/antagonize (XOMA 247), are designed to treat various diseases that result from the continuous over-production of or inappropriate reaction to insulin. XOMA 3AB is a multi-antibody product designed to neutralize the potent of the botulinum toxins, Type A, which causes paralysis and is a bioterrorism threat. The company’s anti-botulism program also includes additional product candidates and is the first of its kind to combine multiple human antibodies in each product candidate to target a spectrum of the toxic botulinum toxins, including the three toxic serotypes, Types A, B, and E. The National Institute of Allergy and Infectious Diseases has completed a Phase 1 trial of XOMA 3AB. XOMA 629 is a topical anti-bacterial formulation of a peptide derived from bactericidal/permeability-increasing protein (BPI), an integral part of the protective human immune system.

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $4.30 USD -0.025

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €7.55 EUR +0.01
BioInvent International AB kr2.56 SEK -0.02
Dyax Corp $15.04 USD +0.52
Intrexon Corp $27.89 USD +0.31
PDL BioPharma Inc $7.62 USD -0.0801
View Industry Companies
 

Industry Analysis

XOMA

Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit www.xoma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.